Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Expenses: 2019-2024

Historic Operating Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $382.5 million.

  • Relay Therapeutics' Operating Expenses fell 16.58% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.4 million, marking a year-over-year decrease of 13.92%. This contributed to the annual value of $382.5 million for FY2024, which is 4.03% down from last year.
  • Latest data reveals that Relay Therapeutics reported Operating Expenses of $382.5 million as of FY2024, which was down 4.03% from $398.5 million recorded in FY2023.
  • Over the past 5 years, Relay Therapeutics' Operating Expenses peaked at $398.5 million during FY2023, and registered a low of $138.4 million during FY2020.
  • Over the past 3 years, Relay Therapeutics' median Operating Expenses value was $382.5 million (recorded in 2024), while the average stood at $360.6 million.
  • As far as peak fluctuations go, Relay Therapeutics' Operating Expenses soared by 165.60% in 2021, and later fell by 18.24% in 2022.
  • Relay Therapeutics' Operating Expenses (Yearly) stood at $138.4 million in 2020, then soared by 165.60% to $367.7 million in 2021, then dropped by 18.24% to $300.7 million in 2022, then spiked by 32.56% to $398.5 million in 2023, then dropped by 4.03% to $382.5 million in 2024.